Purpose: The gold standard for the treatment of complex (TASC II C and D) atherosclerotic aortoiliac lesions is still open surgical repair. Endovascular techniques have a lower mortality and morbidity rate but this comes at the cost of worse patency rates when compared with open repair. Improved short- and mid-term results have been reported using the covered endovascular reconstruction of aortic bifurcation (CERAB) technique. The aim of this study was to report our initial experience with the CERAB technique and report long-term patency rates.

Materials And Methods: All patients treated with the CERAB technique between 2012 and 2018 were prospectively registered in an institutional database and included in this study. Patient demographics, characteristics, symptoms, procedural, and follow-up details were collected and analyzed retrospectively. Perioperative complications and reinterventions were also identified. The Kaplan-Meier survival method was used to assess cumulative rates of patency.

Results: A total of 44 patients were treated with the CERAB technique and included in this study. The majority of the treated aortoiliac occlusions were classified as complex: TASC II C (n=7; 15.9%) or TASC II D (n=25; 56.8%). Primary patency rate at 60 months was 83.3%, assisted primary patency was 90.9% and secondary patency 95%. No significant differences were found in patency rates comparing noncomplex (TASC II A and B) and complex (TASC II C and D) aortoiliac lesions. Seven patients (15.9%) required at least one additional procedure to maintain either assisted primary patency or secondary patency during follow-up. The 30-day complication rate in this series was 20.5% (n=9), of which 55.6% (n=5) were minor complications. All major 30-day complications (n=4) occurred during or directly after the CERAB procedure. Thirty-day mortality was 0%. No limb occlusions occurred within 30 days of the procedure.

Conclusion: Good long-term patency rates can be achieved with the CERAB technique to treat aortoiliac stenosis or occlusions while maintaining advantages associated with endovascular interventions. This remains true even when a CERAB is used to treat complex aortoiliac lesions. An endo-first approach to treat complex aortoiliac lesions seems viable.

Download full-text PDF

Source
http://dx.doi.org/10.1177/15266028211028210DOI Listing

Publication Analysis

Top Keywords

cerab technique
20
aortoiliac lesions
16
complex tasc
12
patency rates
12
primary patency
12
patency
9
covered endovascular
8
endovascular reconstruction
8
reconstruction aortic
8
aortic bifurcation
8

Similar Publications

Article Synopsis
  • The study investigated the two-year outcomes of the covered endovascular reconstruction (CERAB) procedure for patients with complex aortoiliac occlusive disease, focusing on a group of 40 patients.
  • All patients had a 100% technical success rate with notable improvements in clinical symptoms observed during the follow-up period.
  • The patency rates at 36 months were favorable, with primary patency at 85%, indicating that CERAB is effective for treating advanced aorto-occlusive conditions.
View Article and Find Full Text PDF
Article Synopsis
  • Treating atherosclerotic occlusive disease in the infrarenal aorta is challenging, with traditional open surgery posing high risks for morbidity and mortality.
  • The American College of Cardiology (ACC)/American Heart Association (AHA) classification helps assess patient risk, especially benefiting high-risk patients through advancements in endovascular technologies.
  • Minimally invasive methods, such as chimney-CERAB, have been effectively used to treat patients with aortoiliac occlusive disease while preserving key blood vessels like the inferior mesenteric artery.
View Article and Find Full Text PDF
Article Synopsis
  • This review evaluated the effectiveness and safety of bifurcated endografts for treating aortoiliac disease (AOID) by analyzing multiple studies across various databases.* -
  • Ten studies involving 365 patients primarily used the AFX endograft, showing high primary patency rates at 12, 24, and 36 months, with estimates around 90-94% and low rates of major complications.* -
  • While the initial findings suggest that bifurcated endografts are a promising option for AOID treatment, further research is needed to conclusively determine their long-term efficacy and safety.*
View Article and Find Full Text PDF

Background And Aims: There has been hesitancy among people with regard to accepting vaccines, especially that of coronavirus disease-2019 (COVID-19). This hesitancy is aggravated by the different vaccine alternatives available and what one considers before choosing a particular vaccine. The aim of this article was to investigate some driving factors that can influence an individual's COVID-19 vaccine preference in the presence of other alternatives, using some specific vaccine characteristics.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the effectiveness of BeGraft and Solaris stent grafts during a specific endovascular treatment called BS-CERAB, aimed at patients with aortoiliac occlusive disease from January 2020 to December 2023.
  • - A total of 42 patients (mostly men, average age 72) participated, with symptoms mainly including intermittent claudication and critical limb ischemia, and all procedures were successful with an average follow-up of 14 months.
  • - Results showed improvement in blood flow (ABI increase) and promising patency rates at 3, 6, and 12 months post-surgery, although active cancer was identified as a risk factor for restenosis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!